, Volume 4, Issue 2, pp 68-74

Antiviral therapy in the HCV-coinfected patient with HIV and/or HBV

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access

Abstract

Coinfection of hepatitis C virus (HCV)-infected patients with HIV or hepatitis B virus (HBV) is common because of shared modes of transmission. Coinfection with HBV or HIV has been shown to accelerate the course of chronic hepatitis C and facilitate progression to cirrhosis and hepatocellular carcinoma. Currently, the combination of pegylated interferon and ribavirin is the best available treatment in HIV/HCV-coinfected patients. The optimal treatment of HCV in persons with HBV coinfection has not been defined but may include pegylated interferon alpha plus ribavirin initially, followed by oral anti-HBV agents, such as lamivudine or adefovir, or both.